Please assess the completion status of the following clinical trial:

Trial Title: Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Signed Written Informed Consent~* Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir~* Subjects participating in Daclatasvir and/or Asunaprevir studies (ie, protocol numbers beginning with AI443, AI444 or AI447) may enroll regardless of virologic response~* Completed the required post-treatment follow-up period in previous study~* Must enroll in this study within 6 months of completing previous BMS study or within 6 months of protocol availability at the clinical site~* Men and women, ages 18 and older~Exclusion Criteria:~* Subject must not have been treated with any antiviral or immunomodulatory drug for chronic hepatitis C (CHC) after completion of the previous study during which Asunaprevir and/or Daclatasvir were administered~* Subject must not be participating in any other trial, excluding non-interventional trials~* Prisoners or subjects who are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subjects with chronic hepatitis C (Type: None): Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C

Based on this trial design, predict the completion outcome and termination type (if applicable).